- Home
- HOG vs OGN Comparison
HOG vs OGN Comparison
Compare HOG & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOG
- OGN
- Stock Information
- Founded
- HOG 1903
- OGN 1923
- Country
- HOG United States
- OGN United States
- Employees
- HOG N/A
- OGN N/A
- Industry
- HOG Motor Vehicles
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- HOG Consumer Discretionary
- OGN Health Care
- Exchange
- HOG Nasdaq
- OGN Nasdaq
- Market Cap
- HOG 3.3B
- OGN 2.7B
- IPO Year
- HOG N/A
- OGN N/A
- Fundamental
- Price
- HOG $26.98
- OGN $6.75
- Analyst Decision
- HOG Buy
- OGN Buy
- Analyst Count
- HOG 7
- OGN 3
- Target Price
- HOG $29.14
- OGN $17.33
- AVG Volume (30 Days)
- HOG 1.4M
- OGN 6.8M
- Earning Date
- HOG 11-04-2025
- OGN 10-30-2025
- Dividend Yield
- HOG 2.67%
- OGN 1.19%
- EPS Growth
- HOG N/A
- OGN N/A
- EPS
- HOG 1.93
- OGN 2.69
- Revenue
- HOG $4,474,610,000.00
- OGN $6,281,000,000.00
- Revenue This Year
- HOG N/A
- OGN N/A
- Revenue Next Year
- HOG $3.94
- OGN $0.65
- P/E Ratio
- HOG $14.01
- OGN $2.51
- Revenue Growth
- HOG N/A
- OGN N/A
- 52 Week Low
- HOG $20.45
- OGN $6.18
- 52 Week High
- HOG $35.21
- OGN $19.05
- Technical
- Relative Strength Index (RSI)
- HOG 46.59
- OGN 23.64
- Support Level
- HOG $26.71
- OGN $6.18
- Resistance Level
- HOG $28.25
- OGN $9.28
- Average True Range (ATR)
- HOG 0.78
- OGN 0.37
- MACD
- HOG 0.04
- OGN -0.31
- Stochastic Oscillator
- HOG 45.73
- OGN 16.10
About HOG Harley-Davidson Inc.
Harley-Davidson is a leading global manufacturer of heavyweight motorcycles across the custom, cruising, and touring segments, as well as related merchandise, parts, and accessories. In recent years, the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand. Its captive finance arm, Harley-Davidson Financial Services, provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley captured around 37% of the heavyweight domestic market in 2024.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.